Stay updated with breaking news from Active Ingredients. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
KLR Investment Advisors LLC purchased a new position in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY – Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 6,605 shares of the company’s stock, valued at approximately $442,000. A number of other large investors have also […]
Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) issued its earnings results on Wednesday. The company reported $0.99 EPS for the quarter, beating the consensus estimate of $0.88 by $0.11, MarketWatch Earnings reports. Dr. Reddy’s Laboratories had a return on equity of 20.97% and a net margin of 19.26%. The business had revenue of $867.00 […]
Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) issued its earnings results on Wednesday. The company reported $0.99 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.11, MarketWatch Earnings reports. The business had revenue of $867.00 million for the quarter, compared to the consensus estimate of $827.81 million. Dr. Reddy’s Laboratories had […]
Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported $0.99 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.11, MarketWatch Earnings reports. The company had revenue of $867.00 million for the quarter, compared to analyst estimates of $827.81 million. Dr. Reddy’s […]
While Dr Reddy's recorded its highest-ever quarterly revenue in Q3, most of the growth was fueled by a higher-than-expected contribution from cancer drug Revlimid while the base US and India business delivered a subpar performance.